Caldolor® Proves to be a Safe and Effective Opioid-Sparing Option for Pain Management in Seniors
Recent findings from a significant study conducted by Cumberland Pharmaceuticals Inc. showcase Caldolor® (intravenous ibuprofen) as a promising alternative for pain management in older adults. The analysis, which is particularly relevant considering the increasing number of surgeries performed on this demographic, evaluated safety and effectiveness metrics for patients aged 60 and above. The research uncovered a notable 23% reduction in opioid usage post-surgery, a critical consideration given the heightened risks associated with opioid use in older populations.
Understanding the Need for Non-Opioid Alternatives
Pain management for older patients necessitates a unique approach; they often experience amplified sensitivity to opioids and face a greater likelihood of adverse side effects. Unfortunately, older adults are frequently underrepresented in clinical trials, making data like this study essential for drawing attention to their specific needs. As approximately one-third of all outpatient surgeries are performed on older patients, finding effective solutions is vital.
The study comprised a post-hoc subgroup analysis derived from four prospective clinical trials where Caldolor was utilized to address pain and fever in hospitalized individuals. Ultimately, 591 patients were included for efficacy analysis, while safety was assessed across a larger cohort of 1,041 participants.
Dr. Tong Joo Gan from MD Anderson Cancer Center acknowledged the compelling findings, stating, "These results provide clear evidence that intravenous ibuprofen is not only safe but also effective for managing post-operative pain in older patients. The significant drop in opioid consumption is paramount for this at-risk group, susceptible to opioid-related adverse events such as falls and respiratory complications."
Key Findings and Implications for Pain Management in Older Adults
The study yielded several noteworthy insights:
Dr. Stephen Southworth emphasized the necessity of non-opioid analgesics, stating that Caldolor alleviates pain effectively while mitigating the requirement for opioids, promoting better recovery outcomes in the aging population. Given that a considerable portion of surgery-related pain is inflammatory, Caldolor serves as an essential part of multi-modal pain management strategies.
These findings reinforce Cumberland Pharmaceuticals’ dedication to enhancing pain management options across various demographics, particularly as the worldwide elderly population expands. In light of these encouraging results, Cumberland intends to engage healthcare providers to disseminate this pivotal information.
Caldolor has previously proven itself effective in other patient groups, including infants, and is FDA-approved for managing mild to moderate pain, as an adjunct to stronger opioids, and for reducing fever in patients aged three months and older. These recent results shine a light on Caldolor’s vital role in addressing the needs of older adults, potentially transforming pain management practices today.
Further details about Cumberland's comprehensive range of approved products can be found at www.cumberlandpharma.com.
Understanding the Need for Non-Opioid Alternatives
Pain management for older patients necessitates a unique approach; they often experience amplified sensitivity to opioids and face a greater likelihood of adverse side effects. Unfortunately, older adults are frequently underrepresented in clinical trials, making data like this study essential for drawing attention to their specific needs. As approximately one-third of all outpatient surgeries are performed on older patients, finding effective solutions is vital.
The study comprised a post-hoc subgroup analysis derived from four prospective clinical trials where Caldolor was utilized to address pain and fever in hospitalized individuals. Ultimately, 591 patients were included for efficacy analysis, while safety was assessed across a larger cohort of 1,041 participants.
Dr. Tong Joo Gan from MD Anderson Cancer Center acknowledged the compelling findings, stating, "These results provide clear evidence that intravenous ibuprofen is not only safe but also effective for managing post-operative pain in older patients. The significant drop in opioid consumption is paramount for this at-risk group, susceptible to opioid-related adverse events such as falls and respiratory complications."
Key Findings and Implications for Pain Management in Older Adults
The study yielded several noteworthy insights:
- - Caldolor treatment resulted in a 24% reduction in resting pain and a 20% decrease in pain during movement compared to a placebo within 6 to 24 hours post-surgery.
- - A marked 23.2% reduction in total morphine requirements was identified in patients treated with Caldolor, presenting a substantial advantage.
- - Notably, adverse effects were less pronounced among Caldolor-treated patients, recorded at 55%, compared to 90% in the placebo group, with no significant uptick in gastrointestinal or cardiovascular issues.
- - Comparatively, the efficacy and safety of Caldolor remained consistent across older and younger patient groups, despite older patients receiving higher cumulative doses.
Dr. Stephen Southworth emphasized the necessity of non-opioid analgesics, stating that Caldolor alleviates pain effectively while mitigating the requirement for opioids, promoting better recovery outcomes in the aging population. Given that a considerable portion of surgery-related pain is inflammatory, Caldolor serves as an essential part of multi-modal pain management strategies.
These findings reinforce Cumberland Pharmaceuticals’ dedication to enhancing pain management options across various demographics, particularly as the worldwide elderly population expands. In light of these encouraging results, Cumberland intends to engage healthcare providers to disseminate this pivotal information.
Caldolor has previously proven itself effective in other patient groups, including infants, and is FDA-approved for managing mild to moderate pain, as an adjunct to stronger opioids, and for reducing fever in patients aged three months and older. These recent results shine a light on Caldolor’s vital role in addressing the needs of older adults, potentially transforming pain management practices today.
Further details about Cumberland's comprehensive range of approved products can be found at www.cumberlandpharma.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.